Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients

Transplantation. 2023 Aug 1;107(8):e215-e218. doi: 10.1097/TP.0000000000004655. Epub 2023 Jul 20.

Authors

Ilies Benotmane^{1

2}, Jérôme Olagne¹, Gabriela Gautier-Vargas¹, Noëlle Cognard¹, Françoise Heibel¹, Laura Braun-Parvez¹, Nicolas Keller¹, Jonas Martzloff¹, Peggy Perrin¹, Romain Pszczolinski¹, Bruno Moulin^{1

2}, Samira Fafi-Kremer^{2

3}, Sophie Caillard^{1

2}

Affiliations

¹ Department of Nephrology Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France.
² Inserm UMR S1109 Labex Transplantex, Fédération de Médecine Translationnelle, Strasbourg University, Strasbourg, France.
³ Department of Virology, Strasbourg University Hospital, Strasbourg, France.

No abstract available

MeSH terms

Antibodies, Monoclonal
COVID-19*
Humans
Kidney Transplantation* / adverse effects
Transplant Recipients

Substances

tixagevimab
cilgavimab
Antibodies, Monoclonal